Evidence map›Paper›PMID 33962652›Full record

ArticleSystematic reviews2021

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review.

Benjamin P Geisler, Lara Zahabi, Adam Edward Lang, Naomi Eastwood, Elaine Tennant, Ljiljana Lukic, Elad Sharon, Hai-Hua Chuang, Chang-Berm Kang, Knakita Clayton-Johnson and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Systematic reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Benjamin P GeislerLudwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany. bgeisler@post.harvard.edu.ORCID 0000-0003-1704-6067
Lara ZahabiMcGill University, Montreal, Canada.
Adam Edward LangMcDonald Army Health Center, Fort Eustis, VA, USA.
Naomi EastwoodWirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
Elaine TennantRoyal North Shore Hospital, Sydney, NSW, Australia.
Ljiljana LukicUniversity Hospital for Infectious Disease Zagreb "Dr. Fran Mihaljevic", Zagreb, Croatia.
Elad SharonNational Cancer Institute, Bethesda, MD, USA.
Hai-Hua ChuangChang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
Chang-Berm KangProof Biotechnologies, Inc., Columbia, SC, USA.
Knakita Clayton-JohnsonPortmore Hospital Complex, Portmore, Jamaica.
Ahmed AljaberiBrigham and Women's Hospital, Boston, MA, USA.
Haining YuUniversity of California San Francisco Medical Center, San Francisco, CA, USA.
Chinh BuiMassachusetts Institute for Technology, Cambridge, MA, USA.
Tuan Le MauInstitute of High Performance Computing, Singapore, Singapore.
Wen-Cheng LiChang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
Debbie TeodorescuMassachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Ludwig Christian HinskeLudwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany.
Dennis L SunCalifornia Polytechnic State University, San Luis Obispo, CA, USA.
Farrin A ManianMassachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Adam G DunnUniversity of Sydney, Sydney, NSW, Australia.

Funding

Bundesministerium für Bildung und Forschung 01ZZ1603[A-D]Bundesministerium für Bildung und Forschung 01ZZ1804[A-I]
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19.

methodsThis systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. DISCUSSION: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review.

trial registrationPROSPERO 2020 CRD42020175648.

Indexed as

COVID-19Drug RepositioningHumansSARS-CoV-2Systematic Reviews as TopicCOVID-19MERS-CoVMiddle East respiratory syndrome CoronavirusRepurposedRepurposingSARSSARS-CoV2Severe acute respiratory syndrome

Identifiers

PMID33962652
PMCPMC8103882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.